Familial Hemophagocytic Lymphohistiocytosis Presenting as Hydrops Fetalis

Abstract

Background Familial hemophagocytic lymphohistiocytosis (FLH) is an autosomal recessive disorder of immune regulation that leads to a hyperinflammatory syndrome. Fetal onset FHL is extremely rare and is considered to be the most severe form of FHL.

Case We report a preterm case of FHL that presented as hydrops fetalis. The infant was treated with a chemotherapy regimen based on the HLH-2004 protocol from the third day of life. However, he had persistent cytopenia and died on the 18th day of life due to bacteremia. The detection of defective perforin expression in the patient's natural killer cells and mutations in the PRF1 gene resulted in a molecular diagnosis of FHL.

Conclusion We suggest that early diagnosis and the development of an appropriate immunosuppressive strategy that can induce and maintain remission until hematopoietic stem cell transplantation can be performed are required to improve the outcomes of fetal onset FHL.

Keywords

familial hemophagocytic lymphohistiocytosis - hydrops fetalis - hepatosplenomegaly - cytopenia - immunosuppressive chemotherapy

• References

• 1 Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007; 166 (2) 95-109
• 2 Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12 (2) 435-444
• 3 zur Stadt U, Rohr J, Seifert W , et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet 2009; 85 (4) 482-492
• 4 Bechara E, Dijoud F, de Saint Basile G, Bertrand Y, Pondarré C. Hemophagocytic lymphohistiocytosis with Munc13-4 mutation: a cause of recurrent fatal hydrops fetalis. Pediatrics 2011; 128 (1) e251-e254
• 5 Aricò M, Janka G, Fischer A , et al; FHL Study Group of the Histiocyte Society. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. Leukemia 1996; 10 (2) 197-203
• 6 Suzuki N, Morimoto A, Ohga S, Kudo K, Ishida Y, Ishii E ; HLH/LCH Committee of the Japanese Society of Pediatric Hematology. Characteristics of hemophagocytic lymphohistiocytosis in neonates: a nationwide survey in Japan. J Pediatr 2009; 155 (2) 235-8.e1
• 7 Henter JI, Horne A, Aricó M , et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48 (2) 124-131
• 8 Isaacs Jr H. Fetal and neonatal histiocytoses. Pediatr Blood Cancer 2006; 47 (2) 123-129
• 9 Maruyama A, Takahashi N, Gunji Y , et al. Congenital hemophagocytic lymphohistiocytosis in a preterm infant: cytokine profile and a review of the disease. J Pediatr Hematol Oncol 2011; 33 (5) e209-e212
• 10 Pachlopnik Schmid J, Ho CH, Chrétien F , et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009; 1 (2) 112-124
• 11 Marsh RA, Allen CE, McClain KL , et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013; 60 (1) 101-109
• 12 Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28 (3) 585-596